Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NBIO Stock Summary
Top 10 Correlated ETFs
NBIO
In the News
Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / May 9, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting held in Chicago on June 2-6, 2023. The poster presentation, entitled "Phase I Study of Pritumumab in Brain Cancer", will take place from 1:15-4:15 PM CDT on June 3rd, during the "Central Nervous Systems Tumors" session in Hall A of McCormick Place Convention Center.
Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration
SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan BioSolutions (together, the "Partners"), are pleased to announce promising new preliminary preclinical results for the COVID-19 vaccine candidate now progressing under joint development by the Partners. Under a research collaboration agreement signed in 2020, Nascent Biotech and Manhattan BioSolutions partnered to discover and develop a safe and affordable COVID-19 vaccination platform based on modifying licensed BCG vaccine technology originally developed for Tuberculosis ("TB"), but with broader utility in protecting against infection from other types of viruses, some of which may have the potential to cause major outbreaks in humans.
Marble Arch Research Publishes Analyst Research Report on Nascent Biotech
VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to highlight the publication of an in-depth analyst research report on Nascent Biotech by equity research firm, Marble Arch Research, Inc, which rated NBIO a "Speculative Buy" under its tiered rating system, and specified a price target of between $0.39-$1.99. The full research report may be found at: https://www.nascentbiotech.com/wp-content/uploads/2021/06/marble-arch-report-6.10.21.pdf The report concludes, "We believe that there is a reasonable investment thesis at hand to indicate that the company's market value can rise significantly as its lead development drug, PTB, progresses through its clinical study journey, which has just begun.
Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to a novel treatment for tachycardia from Milestone Pharma in a $127.5 million agreement.
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab
TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company") has entered into a license agreement (the "Agreement") with BioRay Pharmaceutical Co Ltd ("BioRay"), thereby granting to BioRay exclusive rights to commercialize Nascent's monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America.
Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note
SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce further strides toward the elimination of toxic debt and dilution risk with the preemptive settlement of its outstanding convertible note liability (the "Note") held by Harbor Gate Capital LLC ("Harbor Gate"). Under the terms of the Note, Harbor Gate had the right to redeem the outstanding liability in the form of an equity conversion that presented dilution risk for Nascent shareholders.
Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt
SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that It has paid off and eliminated a major convertible debt note, pre-emptively preventing a dilutive conversion. The note, which was held by JSJ Investments, LLC ("JSJ"), represented over $186k in debt carried pre-conversion on the Company's balance sheet.
Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to evaluate Pritumumab ("PTB") as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Patient enrollment remains open, and the trial continues to recruit new patients for participation.
Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer
SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic asset, as a treatment option for Brain Cancer, including Malignant Primary Brain Tumors and adult Brain Metastases. Screening to enroll patients in the trial is already underway.
Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier
SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce that the Company has officially received allowance for a "Method-of-Use" patent by the US Patent and Trademark Office ("USPTO") for their primary asset, Pritumumab ("PTB"). Specifically, the patent approval is related to PTB's ability to cross the Blood-Brain Barrier ("BBB").
NBIO Financial details
NBIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.01 | 0.01 | 0 | |
Net income per share | -0.05 | -0.12 | -0.02 | 0 | -0.02 | |
Operating cash flow per share | -0.02 | -0.02 | -0.01 | 0 | -0.02 | |
Free cash flow per share | -0.02 | -0.02 | -0.01 | 0 | -0.02 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | -0.02 | -0.08 | -0.01 | -0.01 | -0.01 | |
Tangible book value per share | -0.02 | -0.08 | -0.01 | -0.01 | -0.01 | |
Share holders equity per share | -0.02 | -0.08 | -0.01 | -0.01 | -0.01 | |
Interest debt per share | 0 | 0.01 | 0.01 | 0 | 0.02 | |
Market cap | 5.39M | 9.22M | 4.49M | 6.14M | 6.67M | |
Enterprise value | 5.25M | 9.35M | 4.65M | 6.05M | 6.89M | |
P/E ratio | -3.93 | -2.25 | -3.41 | -41.58 | -2.38 | |
Price to sales ratio | 0 | 0 | 5.98 | 6.14 | 0 | |
POCF ratio | -7.57 | -16.63 | -4.55 | 14.85 | -3.73 | |
PFCF ratio | -7.57 | -16.63 | -4.55 | 14.85 | -3.73 | |
P/B Ratio | -11.17 | -3.21 | -9.49 | -9.15 | -5.15 | |
PTB ratio | -11.17 | -3.21 | -9.49 | -9.15 | -5.15 | |
EV to sales | 0 | 0 | 6.19 | 6.05 | 0 | |
Enterprise value over EBITDA | -3.84 | -2.71 | -3.27 | -9.94 | -3.19 | |
EV to operating cash flow | -7.38 | -16.87 | -4.71 | 14.62 | -3.85 | |
EV to free cash flow | -7.38 | -16.87 | -4.71 | 14.62 | -3.85 | |
Earnings yield | -0.25 | -0.44 | -0.29 | -0.02 | -0.42 | |
Free cash flow yield | -0.13 | -0.06 | -0.22 | 0.07 | -0.27 | |
Debt to equity | 0 | -0.05 | -0.34 | 0 | -0.3 | |
Debt to assets | 0 | 43.14 | 0.22 | 0 | 1.53 | |
Net debt to EBITDA | 0.1 | -0.04 | -0.11 | 0.16 | -0.1 | |
Current ratio | 0.21 | 0 | 0.61 | 0.14 | 0.16 | |
Interest coverage | 0 | -39.79 | -4.16 | -1.36 | -1.25 | |
Income quality | 0.52 | 0.14 | 1.03 | -0.88 | 0.64 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 2.44 | 0.93 | 0 | |
Research and developement to revenue | 0 | 0 | 0.43 | 0.2 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 1.05 | 0.12 | 0 | |
Graham number | 0.13 | 0.47 | 0.05 | 0.01 | 0.08 | |
ROIC | 2.84 | 1.29 | 6.18 | 0.21 | 4.26 | |
Return on tangible assets | -10.41 | -1.27K | -1.75 | -1.4 | -10.98 | |
Graham Net | -0.02 | -0.08 | -0.01 | -0.01 | -0.01 | |
Working capital | -482.16K | -2.88M | -472.51K | -671.48K | -1.3M | |
Tangible asset value | -482.16K | -2.88M | -472.51K | -671.48K | -1.3M | |
Net current asset value | -482.16K | -2.88M | -472.51K | -671.48K | -1.3M | |
Invested capital | 0 | -0.05 | -0.34 | 0 | -0.3 | |
Average receivables | 0 | 0 | 375K | 375K | 0 | |
Average payables | 364.5K | 689.15K | 744.75K | 706.86K | 637.51K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 365 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 1 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 2.84 | 1.42 | 2.78 | 0.22 | 2.16 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.01 | 0 | 0 | -0.01 | 0 | |
Operating cash flow per share | -0.01 | 0 | 0 | 0 | 0 | |
Free cash flow per share | -0.01 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0 | 0 | 0.01 | 0 | |
Book value per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Tangible book value per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Share holders equity per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Interest debt per share | 0.01 | 0.01 | 0 | 0 | 0 | |
Market cap | 23.9M | 7.2M | 6.98M | 18.68M | 28.92M | |
Enterprise value | 23.81M | 7.42M | 7.25M | 17.98M | 28.42M | |
P/E ratio | -4.98 | -3.48 | -3.23 | -5.63 | -35.19 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -38.35 | -18.64 | -42.92 | -54.69 | -87.6 | |
PFCF ratio | -38.35 | -18.64 | -42.92 | -54.69 | -87.6 | |
P/B Ratio | -17.52 | -5.56 | -6.05 | -2.91K | 952.24 | |
PTB ratio | -17.52 | -5.56 | -6.05 | -2.91K | 952.24 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -50.14 | -13.75 | -14.16 | -21.48 | -77.98 | |
EV to operating cash flow | -38.21 | -19.2 | -44.57 | -52.65 | -86.08 | |
EV to free cash flow | -38.21 | -19.2 | -44.57 | -52.65 | -86.08 | |
Earnings yield | -0.05 | -0.07 | -0.08 | -0.04 | -0.01 | |
Free cash flow yield | -0.03 | -0.05 | -0.02 | -0.02 | -0.01 | |
Debt to equity | -0.34 | -0.3 | -0.24 | -47.58 | 4.12 | |
Debt to assets | 0.83 | 1.53 | 3.51 | 0.29 | 0.19 | |
Net debt to EBITDA | 0.19 | -0.4 | -0.52 | 0.84 | 1.37 | |
Current ratio | 0.29 | 0.16 | 0.06 | 0.99 | 1.05 | |
Interest coverage | -0.73 | -1.35 | -2.15 | -6.69 | -14.64 | |
Income quality | 0.74 | 0.75 | 0.3 | 0.41 | 1.61 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.05 | 0.03 | 0.03 | 0 | 0 | |
ROIC | 0.76 | 0 | 0.84 | -3.23 | -2.35 | |
Return on tangible assets | -2.12 | -2.03 | -6.85 | -0.8 | -0.32 | |
Graham Net | -0.01 | -0.01 | -0.01 | 0 | 0 | |
Working capital | -1.36M | -1.3M | -1.16M | -6.41K | 30.37K | |
Tangible asset value | -1.36M | -1.3M | -1.16M | -6.41K | 30.37K | |
Net current asset value | -1.36M | -1.3M | -1.16M | -6.41K | 30.37K | |
Invested capital | -0.34 | -0.3 | -0.24 | -47.58 | 4.12 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 576.05K | 442.69K | 571.19K | 577.17K | 496.92K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.88 | 0.4 | 0.47 | 129.4 | -6.76 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NBIO Frequently Asked Questions
What is Nascent Biotech, Inc. stock symbol ?
Nascent Biotech, Inc. is a US stock , located in Vero beach of Fl and trading under the symbol NBIO
What is Nascent Biotech, Inc. stock quote today ?
Nascent Biotech, Inc. stock price is $0.1845 today.
Is Nascent Biotech, Inc. stock public?
Yes, Nascent Biotech, Inc. is a publicly traded company.